Imatinib, BCR/ABL tyrosine kinase inhibitor (TKI) is the standard therapy in CML-Ph+ patients since its FDA approval in 2001. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.